全文获取类型
收费全文 | 432篇 |
免费 | 22篇 |
国内免费 | 25篇 |
专业分类
儿科学 | 21篇 |
妇产科学 | 8篇 |
基础医学 | 51篇 |
口腔科学 | 6篇 |
临床医学 | 47篇 |
内科学 | 104篇 |
皮肤病学 | 4篇 |
神经病学 | 13篇 |
特种医学 | 58篇 |
外科学 | 62篇 |
综合类 | 7篇 |
预防医学 | 17篇 |
眼科学 | 2篇 |
药学 | 52篇 |
肿瘤学 | 27篇 |
出版年
2022年 | 3篇 |
2021年 | 5篇 |
2020年 | 2篇 |
2019年 | 4篇 |
2018年 | 7篇 |
2017年 | 7篇 |
2016年 | 16篇 |
2015年 | 12篇 |
2014年 | 7篇 |
2013年 | 15篇 |
2012年 | 23篇 |
2011年 | 15篇 |
2010年 | 14篇 |
2009年 | 16篇 |
2008年 | 13篇 |
2007年 | 28篇 |
2006年 | 17篇 |
2005年 | 26篇 |
2004年 | 13篇 |
2003年 | 6篇 |
2002年 | 11篇 |
2001年 | 11篇 |
2000年 | 6篇 |
1999年 | 11篇 |
1998年 | 18篇 |
1997年 | 14篇 |
1996年 | 18篇 |
1995年 | 18篇 |
1994年 | 16篇 |
1993年 | 22篇 |
1992年 | 7篇 |
1991年 | 9篇 |
1990年 | 11篇 |
1989年 | 12篇 |
1988年 | 8篇 |
1987年 | 3篇 |
1986年 | 3篇 |
1985年 | 7篇 |
1984年 | 4篇 |
1983年 | 3篇 |
1982年 | 4篇 |
1981年 | 4篇 |
1980年 | 2篇 |
1979年 | 3篇 |
1978年 | 2篇 |
1976年 | 2篇 |
1975年 | 1篇 |
排序方式: 共有479条查询结果,搜索用时 15 毫秒
101.
102.
We have developed a bispecific antibody that recognizes the CD4 and CD26 antigens simultaneously and that was examined for its ability to target CD4+CD26+T cells. These latter cells constitute the activated component of the CD4+ CD29highCD45RO+ memory T-cell subset that provides help for B-cell Ig synthesis and help for responses against recall antigens. The purified bispecific antibody exhibited an estimated dissociation constant (kd) of 2.4 x 10(-9) mol/L, on comparison with 1.1 x 10(-9) mol/L for anti-CD26, and 1.6 x 10(-10) mol/L for anti-CD4. Surface plasmon resonance was used to show the bifunctional capacity of the antibody. On binding 125I-bispecific antibody to phytohemagglutinin (PHA)-activated T cells, 54.4% of the bound antibody was internalized. This was the result of bispecific binding, because monovalent fragments of anti-CD4 and anti-CD26 were not able to modulate antigen or induce internalization using both a fluorescent assay and an 125I-internalization assay. The ability of the bispecific antibody to be internalized was used to deliver a toxin, blocked ricin, specifically to cells that are CD4+CD26+. The inability of monovalent fragments to be internalized formed the basis for our hypothesis that monovalent binding by the bispecific immunotoxin would not result in internalization. Against resting E+ T cells, the bispecific immunotoxin developed a minimal effect. On preactivating the same cells, using phorbol myristate acetate (PMA)/ionomycin on concanavalin A (ConA) or especially PHA, levels of CD26 were upregulated and the immunotoxin effectively inhibited the ability to provide help for B-cell Ig synthesis while leaving intact the CD4-CD26+ and CD4+CD26- populations; an effect observed both functionally and by phenotype. The bispecific antibody proved to be most effective at inhibiting a heterologous mixed leukocyte reaction. We propose that this reagent may form the basis for the rational design of toxins designed to modulate activated T cells from, or directed against, tissue grafts. 相似文献
103.
104.
The radiological findings of ultrasound, CT and MR of a case of bilateral subacromial bursitis with macroscopic rice bodies is described. The previous literature is also reviewed. 相似文献
105.
Mobilization of hematopoietic progenitor cells from allogeneic healthy donors using a new biosimilar G‐CSF (Zarzio®)
下载免费PDF全文
![点击此处可从《Journal of clinical apheresis》网站下载免费的PDF全文](/ch/ext_images/free.gif)
María Luisa Antelo Amaya Zabalza María Piva Sánchez Antón Saioa Zalba Mariví Aznar Cristina Mansilla Natalia Ramírez Eduardo Olavarría 《Journal of clinical apheresis》2016,31(1):48-52
Peripheral blood progenitor cells (PBPCs) have become the major source of hematopoietic progenitor cells for allogeneic transplantation. In February 2008, Zarzio® was approved by the European Medicine Agency for PBPCs mobilization, but this authorization was not based in trials analyzing safety and efficacy for PBPCs mobilization. Since August 2011, Zarzio® has been used at our institution for PBPCs mobilization. In total 36 healthy family donors underwent PBPCs mobilization, 18 with Neupogen® and 18 with Zarzio®. Donor characteristics were equivalent between groups, and no severe adverse effects were registered in the Zarzio® group. The number of CD34 cells collected/Kg recipient body weight was 6.7 × 106 (3.8–11.1) in the Zarzio® group versus 8.4 × 106 (5.6–16.6) in the Neupogen® group (P = 0.04). We collected the minimal target cell dose (2 × 106/kg) in all donors from each group and no significant differences were found in the collection of the optimal cell dose (5 × 106/kg) between groups, although 3/18 (16.6%) donors that received Zarzio® failed to mobilize the optimal cell dose compared with 0% in the Neupogen® group. A total of 35 patients proceeded to transplantation (17 in the Zarzio® and 18 in the Neupogen® groups, respectively). Platelet and neutrophil median time to engraftment was comparable between the two groups. Our retrospective study supports the conclusion that Zarzio® mobilization of PBPCs in healthy donors is safe but perhaps not as effective as the reference Neupogen. However, more prospective trials are required to definitively asses the safety and efficacy of G‐CSF biosimilars for PBPCs mobilization in healthy donors. J. Clin. Apheresis 31:48–52, 2016. © 2015 Wiley Periodicals, Inc. 相似文献
106.
107.
108.
109.
110.
Differential cleavage at three restriction enzyme sites was used to determine the specific binding to DNA of the antitumour antibiotics mithramycin A (MTA), chromomycin A3 (CRO) and six chromophore-modified analogues bearing shorter side chains attached at C-3, instead of the pentyl chain. All these antibiotics were obtained through combinatorial biosynthesis in the producer organisms. MTA, CRO and their six analogues showed differences in their capacity for inhibiting the rate of cleavage by restriction enzymes that recognize C/G-rich tracts. Changes in DNA melting temperature produced by these molecules were also analyzed, as well as their antiproliferative activities against a panel of colon, ovarian and prostate human carcinoma cell lines. Moreover, the cellular uptake of several analogues was examined to identify whether intracellular retention was related to cytotoxicity. These experimental approaches provided mutually consistent evidence of a seeming correlation between the strength of binding to DNA and the antiproliferative activity of the chromophore-modified molecules. Four of the analogues (mithramycin SK, mithramycin SDK, chromomycin SK and chromomycin SDK) showed promising biological profiles. 相似文献